Skip to main content
Erschienen in: Heart Failure Reviews 3/2014

01.05.2014

Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases

verfasst von: Adam Mohmand-Borkowski, W. H. Wilson Tang

Erschienen in: Heart Failure Reviews | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

While atrial fibrillation is common comorbidity in patients with cardiomyopathy and heart failure, diagnosis and management often focuses on tackling rate and rhythm control rather than elucidating pathogenic mechanisms related to underlying myocardial substrates. This review summarizes our current understanding of the natural history of cardiomyopathies presenting with atrial fibrillation, and the importance of managing underlying cardiomyopathic condition as diagnostic and treatment strategy for atrial fibrillation.
Literatur
1.
Zurück zum Zitat Wang TJ et al (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham heart study. Circulation 107:2920–2925PubMedCrossRef Wang TJ et al (2003) Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham heart study. Circulation 107:2920–2925PubMedCrossRef
3.
Zurück zum Zitat Kannel WB et al (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(8A):2N–9NPubMedCrossRef Kannel WB et al (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82(8A):2N–9NPubMedCrossRef
4.
Zurück zum Zitat Tedesco MA et al (2001) Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol 24:603–607PubMedCrossRef Tedesco MA et al (2001) Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol 24:603–607PubMedCrossRef
5.
Zurück zum Zitat Hammwohner M, Goette A (2011) Evidence for mechano-electric coupling from clinical trials on AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 395–401 Hammwohner M, Goette A (2011) Evidence for mechano-electric coupling from clinical trials on AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 395–401
6.
Zurück zum Zitat Kalifa J et al (2003) Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 108:668–671PubMedCrossRef Kalifa J et al (2003) Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 108:668–671PubMedCrossRef
7.
Zurück zum Zitat Franz MR, Bode F (2011) Acute stretch effects on atrial electrophysiology. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 168–172 Franz MR, Bode F (2011) Acute stretch effects on atrial electrophysiology. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 168–172
8.
Zurück zum Zitat Camm J et al (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429PubMedCrossRef Camm J et al (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429PubMedCrossRef
9.
Zurück zum Zitat Kamkin A et al (2000) Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 48(3):409–420PubMedCrossRef Kamkin A et al (2000) Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 48(3):409–420PubMedCrossRef
10.
Zurück zum Zitat Spach MS et al (2001) Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol 34(Suppl):69–76PubMedCrossRef Spach MS et al (2001) Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol 34(Suppl):69–76PubMedCrossRef
11.
Zurück zum Zitat Schotten U (2011) Mechano-electric coupling from in chronic AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 204–211 Schotten U (2011) Mechano-electric coupling from in chronic AF. In: Kohl P, Sachs F, Franz MR (eds) Cardiac mechano-electric coupling and arrhythmia, 2nd edn. Oxford University Press, Oxford, pp 204–211
14.
Zurück zum Zitat Kottkamp H (2012) Atrial fibrillation substrate: the “unknown species”—from lone atrial fibrillation to fibrotic atrial cardiomyopathy. Heart Rhythm 9(4):481–482PubMedCrossRef Kottkamp H (2012) Atrial fibrillation substrate: the “unknown species”—from lone atrial fibrillation to fibrotic atrial cardiomyopathy. Heart Rhythm 9(4):481–482PubMedCrossRef
15.
Zurück zum Zitat Mahnkopf C et al (2010) Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 7:1475–1481PubMedCentralPubMedCrossRef Mahnkopf C et al (2010) Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm 7:1475–1481PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Oakes RS et al (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119:1758–1767PubMedCentralPubMedCrossRef Oakes RS et al (2009) Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119:1758–1767PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Teh AW et al (2012) Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm 9(4):473–480PubMedCrossRef Teh AW et al (2012) Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm 9(4):473–480PubMedCrossRef
18.
19.
Zurück zum Zitat Darby AE, Dimarco JP (2012) Management of atrial fibrillation in patients with structural heart disease. Circulation 125(7):945–957PubMedCrossRef Darby AE, Dimarco JP (2012) Management of atrial fibrillation in patients with structural heart disease. Circulation 125(7):945–957PubMedCrossRef
20.
Zurück zum Zitat Bunch TJ et al (2008) Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 19:1009–1014PubMedCrossRef Bunch TJ et al (2008) Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 19:1009–1014PubMedCrossRef
21.
Zurück zum Zitat Kilicaslan F et al (2006) Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 3(3):275–280PubMedCrossRef Kilicaslan F et al (2006) Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 3(3):275–280PubMedCrossRef
22.
Zurück zum Zitat Di Donna P et al (2010) Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 12:347–355PubMedCrossRef Di Donna P et al (2010) Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 12:347–355PubMedCrossRef
23.
Zurück zum Zitat Seidman JE, Pyeritz RE, Seidman CE (2012) Inherited causes of cardiovascular disease. In: Bonow R, Mann D, Zipes D, Libby P (eds) Braunwald’s heart disease a textbook of cardiovascular medicine, 9th edn. Elsevier, Amsterdam, pp 70–79CrossRef Seidman JE, Pyeritz RE, Seidman CE (2012) Inherited causes of cardiovascular disease. In: Bonow R, Mann D, Zipes D, Libby P (eds) Braunwald’s heart disease a textbook of cardiovascular medicine, 9th edn. Elsevier, Amsterdam, pp 70–79CrossRef
24.
Zurück zum Zitat Maron BJ et al (2009) Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301(12):1253–1259PubMedCrossRef Maron BJ et al (2009) Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301(12):1253–1259PubMedCrossRef
25.
Zurück zum Zitat Bounce D et al (2011) Natural history of Danon disease. Genet Med 13(6):563–568CrossRef Bounce D et al (2011) Natural history of Danon disease. Genet Med 13(6):563–568CrossRef
26.
Zurück zum Zitat Cheng Z, Cui Q, Tian Z et al (2012) Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 33(5):649–656PubMedCrossRef Cheng Z, Cui Q, Tian Z et al (2012) Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 33(5):649–656PubMedCrossRef
27.
Zurück zum Zitat Gollob MH et al (2002) PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17:229–234PubMedCrossRef Gollob MH et al (2002) PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17:229–234PubMedCrossRef
28.
29.
30.
Zurück zum Zitat Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH (2013) Isolated left ventricular noncompaction controversies in diagnosis. Heart 99(10):681–689PubMedCrossRef Thavendiranathan P, Dahiya A, Phelan D, Desai MY, Tang WH (2013) Isolated left ventricular noncompaction controversies in diagnosis. Heart 99(10):681–689PubMedCrossRef
31.
Zurück zum Zitat Connolly HM, Attenhofer JC (2013) Isolated left ventricular non-compaction. UpToDate Connolly HM, Attenhofer JC (2013) Isolated left ventricular non-compaction. UpToDate
32.
Zurück zum Zitat Ammash NA, Tajik JA (2013) Idiopathic restrictive cardiomyopathy. UpToDate Ammash NA, Tajik JA (2013) Idiopathic restrictive cardiomyopathy. UpToDate
33.
Zurück zum Zitat Falk R, Dubrey S (2010) Amyloid heart disease. In: Gertz MA, Rajkumar SV (eds) Amyloidosis: diagnosis and treatment. Humana Press, Clifton, pp 107–128CrossRef Falk R, Dubrey S (2010) Amyloid heart disease. In: Gertz MA, Rajkumar SV (eds) Amyloidosis: diagnosis and treatment. Humana Press, Clifton, pp 107–128CrossRef
34.
Zurück zum Zitat Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420PubMedCrossRef Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420PubMedCrossRef
35.
Zurück zum Zitat Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497 Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490–2497
36.
Zurück zum Zitat Redfield MM et al (2000) Tachycardia related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for AV node ablation. Mayo Clin Proc 75:790–795PubMedCrossRef Redfield MM et al (2000) Tachycardia related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for AV node ablation. Mayo Clin Proc 75:790–795PubMedCrossRef
37.
Zurück zum Zitat Deshmukh PM et al (2004) Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 13:455–464PubMed Deshmukh PM et al (2004) Association of angiotensin converting enzyme gene polymorphism with tachycardia cardiomyopathy. Int J Mol Med 13:455–464PubMed
38.
Zurück zum Zitat Moe GW et al (1993) Left ventricular myocardial blood flow, metabolism and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 131:294–302 Moe GW et al (1993) Left ventricular myocardial blood flow, metabolism and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. J Lab Clin Med 131:294–302
39.
Zurück zum Zitat Spinale FG et al (1992) Myocardial Na, K-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 24:277–289PubMedCrossRef Spinale FG et al (1992) Myocardial Na, K-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol 24:277–289PubMedCrossRef
40.
Zurück zum Zitat Kloner RA et al (1981) Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci USA 78:7152–7163PubMedCentralPubMedCrossRef Kloner RA et al (1981) Recovery from prolonged abnormalities of canine myocardium salvaged from ischemic necrosis by coronary reperfusion. Proc Natl Acad Sci USA 78:7152–7163PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Huffman C et al (2010) Reversible cardiomyopathies—a review. Transpl Proc 42(9):3673–3678CrossRef Huffman C et al (2010) Reversible cardiomyopathies—a review. Transpl Proc 42(9):3673–3678CrossRef
42.
Zurück zum Zitat Iyer VR (2008) Ventricular dysfunction: tachycardia induced cardiomyopathy. Indian Pacing Electrophysiol J 8(Suppl 1):S122–S129 Iyer VR (2008) Ventricular dysfunction: tachycardia induced cardiomyopathy. Indian Pacing Electrophysiol J 8(Suppl 1):S122–S129
43.
Zurück zum Zitat Watanabe H et al (2008) Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 49(1):39–47PubMedCrossRef Watanabe H et al (2008) Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 49(1):39–47PubMedCrossRef
44.
Zurück zum Zitat Jeong Y et al (2008) Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 31(4):172–178PubMedCrossRef Jeong Y et al (2008) Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 31(4):172–178PubMedCrossRef
45.
Zurück zum Zitat Gentlesk PJ et al (2007) Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18(1):9–14PubMedCrossRef Gentlesk PJ et al (2007) Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18(1):9–14PubMedCrossRef
46.
Zurück zum Zitat Nerheim P et al (2004) Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110(3):247–252PubMedCrossRef Nerheim P et al (2004) Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110(3):247–252PubMedCrossRef
47.
Zurück zum Zitat Ling L et al (2013) Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy following successful ablation. Circ Arrhythm Electrophysiol 6(4):697–704PubMedCrossRef Ling L et al (2013) Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy following successful ablation. Circ Arrhythm Electrophysiol 6(4):697–704PubMedCrossRef
48.
Zurück zum Zitat Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: primary prevention. Europace 13:308–328PubMedCrossRef Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: primary prevention. Europace 13:308–328PubMedCrossRef
49.
Zurück zum Zitat Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part II: secondary prevention. EuroPace 13:610–662PubMedCrossRef Savelieva I, Kakouros N, Kourliouros A, Camm AJ (2011) Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part II: secondary prevention. EuroPace 13:610–662PubMedCrossRef
50.
Zurück zum Zitat Camm J et al (2012) Focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747PubMedCrossRef Camm J et al (2012) Focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747PubMedCrossRef
Metadaten
Titel
Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases
verfasst von
Adam Mohmand-Borkowski
W. H. Wilson Tang
Publikationsdatum
01.05.2014
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 3/2014
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-014-9424-0

Weitere Artikel der Ausgabe 3/2014

Heart Failure Reviews 3/2014 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.